Glucagon-like peptide1 analogues for type 2 diabetes mellitus
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Given the heterogeneity of kratom consumers, the array of products, and limitations in current assessment and testing methods, clinicians may not be equipped for evidence-based practice with respect to patients who use kratom or who may have DSM-5-derived kratom use disorder (KUD)
What Is Semaglutide and How Does It Support Weight Loss
Conclusion China has followed this playbook before: enter at scale, drive down cost, expand access
Detailed mechanisms are subject to ongoing scientific investigation